Ontology highlight
ABSTRACT:
SUBMITTER: Das A
PROVIDER: S-EPMC4570637 | biostudies-literature | 2015
REPOSITORIES: biostudies-literature
Experimental hematology & oncology 20150915
Target specific oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban) are changing the landscape of anticoagulation. The major drawback is the absence of an effective antidote for severe bleedings and/or prior to procedures. Currently there are a few promising antidotes undergoing clinical trials. This review summarized the latest development in idarucizumab, andexanet alpha and PER977. ...[more]